"This MEDPAC report confirms exactly what we have been saying: rising drug prices are putting a colossal burden on America’s health care system and now total nearly 20 percent of health care spending. Without market-based solutions like transparency, competition, and value, we can only expect the problem to get worse.” Read More
“The pharmaceutical industry’s habit of hiking prices on life-saving medications is appalling. Our campaign has been active in drawing attention to the price spikes on naloxone and we welcome this bipartisan effort to expose pharma’s price gouging tactics." Read More
"Drug companies seem to be taking advantage of increased demand for Naloxone during this public health crisis by raising the price of a literally lifesaving medication," said John Rother, executive director of the Campaign for Sustainable Rx Pricing. Read More
"Annual prescription price hikes are driving the overall increase in health care costs and making health care less affordable for Americans. Today's S&P report confirms what we've been saying — these increases in drug cost are unsustainable — and solutions to promote transparency, increase competition, and focus on value must be advanced," said John Rother, executive director of the Campaign for Sustainable Rx Pricing (CSRxP). Read More
“Excessive price hikes on prescription drugs drive up spending year after year with no end in sight. Drug makers' annual habit of demanding a blank check, without reference to any change in value from patients and taxpayers, makes it harder for American families to make ends meet. Ultimately, these price increases make health care more expensive for all of us, even those who don’t use prescription drugs. It’s outrageous.” Read More
“This is further evidence that skyrocketing drug prices are more widespread than a few bad actors. When major drug companies hike prices on common prescription drugs, Americans suffer. Families are forced to decide between paying for prescriptions or paying bills, and that’s wrong.” Read More
"Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It’s unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice.” Read More
"Recently, the FDA took an important first step in acknowledging the need to introduce more competition by prioritizing generic applications where there is no competition. This effort will give patients better access to affordable treatments," said John Rother, executive director of the Campaign for Sustainable Rx Pricing. Read More
“Today’s AARP report provides new evidence that drug companies are raising prescription drug prices on patients indiscriminately. Specialty and branded drugs alike are going up six times faster than inflation. The exorbitant increases make health care more expensive for families, taxpayers, and job creators and put a major strain on federal and state governments. It's going to take market-based policy solutions to deal with this unsustainable trend.” Read More
“Prescription drug cost hikes are not limited to companies run by people like Martin Shkreli; they are commonplace in the pharmaceutical industry. This issue transcends political party lines because consumers, patients, and public programs across the country simply cannot afford higher prices for medication." Read More
“Again and again, drug companies like Pfizer raise prices of prescriptions that have already been on the market for years which hurts patients trying to make ends meet and public programs dealing with difficult budgets. These increases, compounded year after year, are simply unsustainable. It’s not about innovation or research; it’s price gouging.” Read More
This afternoon, the Centers for Medicare & Medicaid Services took an important step in the drug pricing conversation by introducing a tool that will increase transparency. To develop realistic market-based solutions to unsustainable drug prices requires that everyone focus on value and transparency in drug pricing, and this latest effort from CMS is a positive step.” Read More